V160
Biological Vaccine
General payments
$58,862
Research payments
$10,205,154
Through program year 2020, $58,862 in general payments and $10,205,154 in research payments were reported against V160 (Vaccine).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | General | $11,799 | 18 |
| 2020 | Research | $3,624,524 | 3,104 |
| 2019 | General | $47,063 | 35 |
| 2019 | Research | $6,580,630 | 5,057 |
Breakdown
The top 5 of 6 recipients; each share is of general payments naming this product in 2020.
Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.
The top 5 of 6 states; each share is of general payments naming this product in 2020 where a state was reported.
Records
53 general · 8,161 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.